ReWalk Robotics (RWLK) Misses Q4 EPS by 3c

ReWalk Robotics (NASDAQ: RWLK) reported Q4 EPS of ($0.47), $0.03 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $1.61 million versus the consensus estimate of $2.08 million.

“As ReWalk strives to create and lead this new industry, we believe we made solid progress in 2016 to advance our goals. More ReWalk devices are being used at home and in the community than ever before and through our efforts with the U.S. Department of Veterans Affairs, all qualified veterans now have a path to a ReWalk system. Additionally, we are optimistic that our advanced discussions with large national coverage providers in the U.S. and Germany will result in broad coverage policies this year, expanding access to potentially thousands of new users over time,” stated Larry Jasinski, Chief Executive Officer.

“We are also focused on opportunities to treat additional indications and have focused our R&D efforts on our collaboration with Harvard’s Wyss Institute to develop a soft exo-suit designed to meet the needs of stroke victims. As we prepare for our first clinical trial of the soft exo-suit this year, we are excited by the potential of the technology to serve as a new standard of care in treating stroke patients in the rehabilitation setting,” added Jasinski.

“In 2017, we intend to focus on supporting sales growth, securing broad reimbursement coverage, and advancing our product developments efforts,” concluded Jasinski.

For earnings history and earnings-related data on ReWalk Robotics (RWLK) click here.

You May Also Be Interested In

• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• NOV Inc (NOV) Tops Q1 EPS by 3c; offers guidance
• Snap shares surge 26% on earnings beat, optimistic outlook